137 related articles for article (PubMed ID: 15212624)
1. Sarpogrelate: cardiovascular and renal clinical potential.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jul; 13(7):865-74. PubMed ID: 15212624
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potentials of sarpogrelate in cardiovascular disease.
Saini HK; Takeda N; Goyal RK; Kumamoto H; Arneja AS; Dhalla NS
Cardiovasc Drug Rev; 2004; 22(1):27-54. PubMed ID: 14978517
[TBL] [Abstract][Full Text] [Related]
3. Effects of M-1, a Major Metabolite of Sarpogrelate, on 5-HT-Induced Constriction of Isolated Human Internal Thoracic Artery.
Tanaka-Totoribe N; Hidaka M; Gamoh S; Yokota A; Nakamura E; Kuwabara M; Tsunezumi J; Yamamoto R
Biol Pharm Bull; 2020 Dec; 43(12):1979-1982. PubMed ID: 32999137
[TBL] [Abstract][Full Text] [Related]
4. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
Yoshimasu T; Ikeda T; Uede K; Kanazawa N; Furukawa F
J Dermatol; 2012 Jun; 39(6):536-40. PubMed ID: 22077618
[TBL] [Abstract][Full Text] [Related]
5. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model.
Miyata K; Shimokawa H; Higo T; Yamawaki T; Katsumata N; Kandabashi T; Tanaka E; Takamura Y; Yogo K; Egashira K; Takeshita A
J Cardiovasc Pharmacol; 2000 Feb; 35(2):294-301. PubMed ID: 10672864
[TBL] [Abstract][Full Text] [Related]
6. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
7. Effect of sarpogrelate, a selective 5-HT
Lee DH; Chun EJ; Hur JH; Min SH; Lee JE; Oh TJ; Kim KM; Jang HC; Han SJ; Kang DK; Kim HJ; Lim S
Atherosclerosis; 2017 Feb; 257():47-54. PubMed ID: 28068560
[TBL] [Abstract][Full Text] [Related]
8. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system.
Nagatomo T; Rashid M; Abul Muntasir H; Komiyama T
Pharmacol Ther; 2004 Oct; 104(1):59-81. PubMed ID: 15500909
[TBL] [Abstract][Full Text] [Related]
9. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
[TBL] [Abstract][Full Text] [Related]
10. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
Umrani DN; Bodiwala DN; Goyal RK
Mol Cell Biochem; 2003 Jul; 249(1-2):53-7. PubMed ID: 12956398
[TBL] [Abstract][Full Text] [Related]
11. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
Doggrell SA
Expert Opin Investig Drugs; 2003 May; 12(5):805-23. PubMed ID: 12720492
[TBL] [Abstract][Full Text] [Related]
12. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Hironaka E; Hongo M; Sakai A; Mawatari E; Terasawa F; Okumura N; Yamazaki A; Ushiyama Y; Yazaki Y; Kinoshita O
Cardiovasc Res; 2003 Dec; 60(3):692-9. PubMed ID: 14659815
[TBL] [Abstract][Full Text] [Related]
13. Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Hayashi T; Sumi D; Matsui-Hirai H; Fukatsu A; Arockia Rani P J; Kano H; Tsunekawa T; Iguchi A
Atherosclerosis; 2003 May; 168(1):23-31. PubMed ID: 12732383
[TBL] [Abstract][Full Text] [Related]
14. Sarpogrelate treatment reduces restenosis after coronary stenting.
Fujita M; Mizuno K; Ho M; Tsukahara R; Miyamoto A; Miki O; Ishii K; Miwa K
Am Heart J; 2003 Mar; 145(3):E16. PubMed ID: 12660685
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice.
Kim DH; Choi BH; Ku SK; Park JH; Oh E; Kwak MK
PLoS One; 2016; 11(4):e0153965. PubMed ID: 27097221
[TBL] [Abstract][Full Text] [Related]
16. Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Chen YX; Wang WD; Song XJ; Gu YQ; Tian HY; Hu HJ; Zhao JC; Li XQ; Liu CW
Chin Med J (Engl); 2015 Jun; 128(12):1563-6. PubMed ID: 26063354
[TBL] [Abstract][Full Text] [Related]
17. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
Muntasir HA; Bhuiyan MA; Ishiguro M; Ozaki M; Nagatomo T
J Pharmacol Sci; 2006 Oct; 102(2):189-95. PubMed ID: 17031071
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts.
Fujita M; Minamino T; Sanada S; Asanuma H; Hirata A; Ogita H; Okada K; Tsukamoto O; Takashima S; Tomoike H; Node K; Hori M; Kitakaze M
J Mol Cell Cardiol; 2004 Dec; 37(6):1219-23. PubMed ID: 15572052
[TBL] [Abstract][Full Text] [Related]
19. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
Brasil D; Temsah RM; Kumar K; Kumamoto H; Takeda N; Dhalla NS
J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):53-9. PubMed ID: 12000979
[TBL] [Abstract][Full Text] [Related]
20. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Miyazaki M; Higashi Y; Goto C; Chayama K; Yoshizumi M; Sanada H; Orihashi K; Sueda T
J Cardiovasc Pharmacol; 2007 Apr; 49(4):221-7. PubMed ID: 17438407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
